ExOne Opens State-of-the-Art Metal 3D Printing Adoption Center in Europe, Expands Engineering Support
8.7.2021 11:00:00 EEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced it has opened a Metal 3D Printing Adoption Center at its European headquarters in Gersthofen, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210708005298/en/
Eric Bader, Managing Director of ExOne GmbH, says the launch of ExOne's Metal 3D Printing Adoption Center is driven by increased interest by European manufacturers in metal binder jet 3D printing. ExOne’s Adoption Centers now print sand molds and cores for metalcasting customers, as well as metal benchmarks for its metal binder jetting engineering consulting services. (Photo: Business Wire)
The mission of ExOne’s Adoption Centers, which have locations in the U.S., Germany, and Japan, is to allow customers to try binder jet 3D printing for their designs before they decide to buy an ExOne 3D printing system for their own production.
The investment announced today represents an expansion of ExOne’s longtime Adoption Center in Europe, which 3D prints sand molds and cores for metalcasting customers. ExOne’s Metal Adoption Center now offers manufacturers end-to-end engineering services for direct-metal binder jet 3D printing, including benchmarks, design support, and materials, process, and work cell development.
“Now, manufacturers throughout Europe can benefit from locally produced binder jetted metal designs and benchmarks, along with world-class engineering consultation and support,” said John Hartner, ExOne’s CEO. “We encourage manufacturers to take advantage of the high speed, low cost, and industry-leading quality that our patented binder jetting technology can deliver for even the most complex designs.”
“Our centralized location outside of Munich gives manufacturers the opportunity to see metal binder jetting in action and work closely with our expanded metal team on precision metal parts projects,” said Eric Bader, Managing Director, ExOne GmbH. “This expansion is supported by increased interest in metal binder jetting in Europe as the technology matures.”
High-Quality Metal Parts Key Focus of New Center
Binder jetting is a high-speed method of 3D printing in which an industrial inkjet printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time. When printing metals, the final part must be sintered in a furnace to fuse the particles together into a high-density solid object.
All new ExOne metal printers, such as the X1 160Pro manufactured on-site in Gersthofen, are now offered with the company’s patented Triple Advanced Compaction Technology (ACT), which delivers industry-leading accuracy, density, and repeatability in binder jet printing.
ExOne has now qualified more than 20 metal, ceramic, and composite materials for its binder jetting process. More than half of those materials are single-alloy metals, such as 17-4PH, 316L, 304L, M2 Tool Steel, Inconel 718, and more. Most recently, ExOne announced that 6061 aluminum is now a Customer-Qualified material, and titanium is now fast-tracked for qualification in partnership with a global medical device firm.
ExOne’s New Metal 3D Printing Adoption Center will initially focus on the delivery of small-to-medium parts with quality similar to Metal Injection Molding (MIM) in 316L and 17-4PH, with other materials available. To exploring having your part or product metal 3D printed with ExOne technology, contact ExOne through exone.com/EMEAmetal or +49 821 65063 238.
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005298/en/
Contact information
Sarah Webster
724.516.2336
sarah.webster@exone.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
